All AbMole products are for research use only, cannot be used for human consumption.
ATN-161 TFA salt is a novel small peptide inhibitor of integrin α5β1; a beta integrin antagonist with antitumor activity. ATN-161 TFA inhibited VEGF-induced migration and capillary tube formation in hCECs.
In vivo, injection of ATN-161 after laser photocoagulation inhibited CNV leakage and neovascularization to an extent similar to AF564. Furthermore, SD-OCT and histologic examinations indicated that ATN-161 significantly decreased the size of laser-induced lesions. Treatment with the α5β1 signaling inhibitor ATN-161 significantly blunts atherosclerotic plaque development in apolipoprotein E-deficient mice, characterized by reduced vascular cell adhesion molecule-1 expression and macrophage accumulation without affecting fibrous cap size.
 |
Source | Graefes Arch Clin Exp Ophthalmol (2018). Figure 2. ATN-161 |
| Method | western blot assay | |
| Cell Lines | Tet/opsin/VEGF mice | |
| Concentrations | 0.1, 1, and 10 μg/μL | |
| Incubation Time | 24 h | |
| Results | The analysis of western blot results revealed that ATN-161 significantly reduced the expression of integrin 5β1 at concentrations of 1 and 10 μg/μL, and this seemed to present a dose-independent manner |
| Molecular Weight | 711.67 |
| Formula | C25H36F3N9O10S |
| CAS Number | 904763-27-5 |
| Solubility (25°C) | Water 8 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Integrin Products |
|---|
| Volociximab
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs). |
| GSK 3008348 hydrochloride
GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist. |
| HSDVHK-NH2
HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM). |
| LDV
LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. |
| Cyclo(RADfK)
Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
